BenevolentAI Investor Presentation Deck
BEN-2293 -Atopic Dermatitis (AD)
• Atopic dermatitis is the most common chronic
inflammatory skin disease, characterized by intensely
itchy, red, and swollen skin
o Affects 10-20% of children and up to 3% of adults (¹)
o Approximately 60-70% of all cases present with
mild-moderate disease severity (2)
o Prevalence is rising, with market value in 7MM
forecast to exceed $14 billion by expected launch
of BEN-2293 in 2028(¹)
Skin inflammation and chronic pruritus associated
with atopic dermatitis negatively impact quality of life
and psychosocial well-being
• Clear unmet need in mild to moderate patient
segment for treatment addressing itch and
inflammation, without side effects of steroids
Source: (1) GlobalData- Atopic Dermatitis: Global Drug Forecast and Market Analysis to 2027; Evaluate
Pharma - Eczema/Dermatitis: Worldwide Sales 2026 (2) GlobalData-Atopic Dermatitis: Epidemiology
Forecast to 2027
BEN-2293: A potent PanTrk antagonist developed to
relieve inflammation and provide rapid itch resolution
in patients with AD
• BEN-2293 is a PanTrk inhibitor targeting TrkA, B and C
receptors. The Trk receptors were identified as part of an
effort to find mediators of both itch and inflammation
in AD. Using our Molecular Design expertise we were
able to design a PanTrk inhibitor, equipotent against the
3 receptors
BEN-2293 is expected to treat atopic dermatitis by:
inhibiting itch signaling and blocking nerve sensitization
(TrkA) in addition to inhibiting Th1 and Th2-mediated
dermal inflammation (TrkB, TrkC)
• BEN-2293 will target Mild, Moderate and Severe Atopic
Dermatitis patients, addressing unmet need in the
treatment of mild to moderate Atopic Dermatitis as a
steroid sparing alternative and in more severe patients
undergoing treatment with biologics (e.g. dupilumab)
that require add-on treatment
HPA - Hypothalamus, Pituitary, Adrenal
Benevolent 10View entire presentation